FOXA1 in prostate cancer

Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Hui-Yu, Ding, Lei, Zhou, Tian-Ren, Yan, Tao, Li, Jie, Liang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226509/
https://www.ncbi.nlm.nih.gov/pubmed/36018068
http://dx.doi.org/10.4103/aja202259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226509/
https://www.ncbi.nlm.nih.gov/pubmed/36018068
http://dx.doi.org/10.4103/aja202259

Ejemplares similares